Press Releases May 18, 2026 08:30 AM

Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference

Fortress Biotech to Feature CEO Lindsay Rosenwald in AGP Virtual Healthcare Conference Fireside Chat

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
FBIO

Fortress Biotech announced that its CEO, Lindsay A. Rosenwald, M.D., will participate in a fireside chat at the A.G.P. Annual Virtual Healthcare Conference on May 20, 2026. The company highlighted its diverse portfolio spanning oncology, dermatology, and rare diseases, along with strategic partnerships with leading research institutions and biopharmaceutical companies.

Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
FBIO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Fortress Biotech's CEO to speak at a major virtual healthcare conference, potentially increasing visibility among investors and industry stakeholders.
  • The company focuses on acquiring and advancing biopharmaceutical assets across oncology, dermatology, and rare diseases, aiming to build long-term shareholder value through diversified revenue streams.
  • Fortress has established partnerships with prominent institutions and biopharmaceutical companies, which may enhance its research and development capabilities.

MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference, taking place on Wednesday, May 20, 2026. The fireside chat is scheduled to begin at 12:20pm ET.

To register for the conference, visit the A.G.P. Registration Link.

About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber Cancer Center and Sentynl Therapeutics. For more information, visit www.fortressbiotech.com.

Company Contact:
Jaclyn Jaffe
Fortress Biotech, Inc.
(781) 652-4500
ir@fortressbiotech.com

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com  


Risks

  • The announcement is primarily about a conference participation and does not include new product updates or financial results, which might limit immediate impact on stock performance.
  • The biopharmaceutical sector faces inherent risks such as regulatory approvals, clinical trial outcomes, and competitive pressures, which remain ongoing uncertainties for Fortress Biotech.
  • Market reception to conference participation is uncertain and may not translate into significant investor action without substantive news or milestones.

More from Press Releases

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026